179eP PARP inhibitor–associated therapy-related myeloid neoplasms in ovarian cancer: A multi-centre case series from Eastern India
Though Poly (ADP-ribose) polymerase inhibitors (PARPi) are used in ovarian cancer with DNA damage repair pathway and improve survival outcomes, therapy-related myeloid neoplasms (t-MDS/AML) are emerging as a rare but serious complication. Clinico-demographic profile and therapy have been challenging due to paucity of literature, especially from low middle income countries (LMIC).
Authors
- N. Singh
- L. Moharana
- I. Rastogi
- S.K. Swain
- L. Samantaray
- S K Mishra
- G. Biswas
- S.S. Panda
- S.S. Mohanty
- S. Harankhedkar
- V. Agarwala
- S. Dash
- M. Chandrakanth
- K. Ygl
Institutions
- Tamil Nadu Dr. M.G.R. Medical University (IN)
- Mahesh Bhattacharyya Homeopathic Medical College and Hospital (IN)
- Sparsh Hospital (IN)
- All India Institute of Medical Sciences Bhubaneswar (IN)
- Institute of Medical Sciences and Sum Hospital (IN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108225
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00